Loading clinical trials...
Loading clinical trials...
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain
Conditions
Interventions
OG-6219
Placebo
Locations
86
United States
Central Research Associates LLC dba Flourish Research
Birmingham, Alabama, United States
UAB Center for Women's Reproductive Health
Birmingham, Alabama, United States
Olympia Clinical Trials
Los Angeles, California, United States
Yale Fertility Center
Orange, Connecticut, United States
Physician Care Clinical Research, LLC
Sarasota, Florida, United States
University of South Florida
Tampa, Florida, United States
Start Date
October 25, 2022
Primary Completion Date
May 28, 2025
Completion Date
May 28, 2025
Last Updated
May 29, 2025
NCT05951452
NCT06611501
NCT05726786
NCT07241637
NCT04567771
NCT07215130
Lead Sponsor
Organon and Co
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions